Grape seed extract supplementation in non-alcoholic fatty liver disease

被引:2
|
作者
Ghanbari, Parisa [1 ]
Alboebadi, Roghayeh [1 ]
Bazyar, Hadi [2 ,3 ]
Raiesi, Davoud [4 ]
Zarejavid, Ahmad [5 ]
Azadbakht, Mohammad Karim [6 ]
Karimi, Mahdi [1 ]
Razmi, Hamidreza [1 ]
机构
[1] Ahvaz Jundishapur Univ Med Sci, Student Res Comm, Ahvaz, Iran
[2] Sirjan Sch Med Sci, Dept Publ Hlth, Sirjan, Iran
[3] Student Res Comm, Sirjan Sch Med Sci, Sirjan, Iran
[4] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Internal Med, Ahvaz, Iran
[5] Ahvaz Jundishapur Univ Med Sci, Clin Sci Res Inst, Nutr & Metab Dis Res Ctr, Ahvaz, Iran
[6] Sirjan Sch Med Sci, Dept Basic Sci, Sirjan, Iran
关键词
non-alcoholic fatty liver disease; oxidative stress; quality of life; grape seed extract; ANTIOXIDANT STATUS; OXIDATIVE STRESS; DOUBLE-BLIND; INCREASES; QUESTIONNAIRE; POLYPHENOLS; VALIDATION;
D O I
10.1024/0300-9831/a000805
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Despite rising non-alcoholic fatty liver disease (NAFLD) prevalence and its impact on liver health, there's a lack of studies on grape seed extract's (GSE) effect on oxidative stress and quality of life (QoL) in NAFLD patients. This study aims to fill this gap by the potential benefits of GSE in reducing oxidative stress and improving QoL. Methods: In this randomized clinical trial study, fifty patients with NAFLD were randomly assigned to receive either 2 tablets of GSE containing 250 mg of proanthocyanidins or placebo (25 participants in each group) for two months. QoL was evaluated using the SF-36 questionnaire, and oxidative stress variables (TAC, MDA, SOD, GPx, CAT, and IL-6) were measured at the beginning and end of the study. Results: Compared with the control group, the group supplemented with GSE experienced greater reductions in IL-6 and MDA (3.14 +/- 1.43 pg/ml vs. 2.80 +/- 0.31 pg/ml; 4.16 +/- 2.09 mu M vs. 4.59 +/- 1.19 mu M, p for all <0.05), as well as greater increases in TAC, SOD, and GPx levels (0.18 +/- 0.08 mM vs. -0.03 +/- 0.09 mM; 10.5 +/- 6.69 U/ml vs. 8.93 +/- 1.63 U/ml; 14.7 +/- 13.4 U/ml vs. 8.24 +/- 3.03 U/ml, p for all <0.05). Furthermore, the QoL questionnaire showed that physical limitations, general health, and total physical health were significantly improved in the GSE group compared with the placebo (17.0 +/- 42.0 vs. -12.0 +/- 37.5; 3.80 +/- 14.8 vs. -3.92 +/- 9.55; 5.08 5.26 vs. -7.01 +/- 13.7, p for all <0.05). Conclusions: GSE can be effective in improving oxidative stress and QoL in patients with NAFLD. More studies are needed to confirm the results of this study.
引用
收藏
页码:365 / 376
页数:12
相关论文
共 50 条
  • [31] Non-alcoholic fatty liver disease and liver secretome
    Khan, Muhammad Sohaib
    Lee, Choongho
    Kim, Sang Geon
    ARCHIVES OF PHARMACAL RESEARCH, 2022, 45 (12) : 938 - 963
  • [32] Liver transplantation for non-alcoholic fatty liver disease
    Germani, Giacomo
    Becchetti, Chiara
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2018, 64 (02) : 138 - 146
  • [33] Liver transplantation and non-alcoholic fatty liver disease
    Zezos, Petros
    Renner, Eberhard L.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15532 - 15538
  • [34] Non-alcoholic fatty liver disease and liver transplantation
    Khan, Reenam S.
    Newsome, Philip N.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1208 - 1223
  • [35] Non-alcoholic fatty liver disease and liver secretome
    Muhammad Sohaib Khan
    Choongho Lee
    Sang Geon Kim
    Archives of Pharmacal Research, 2022, 45 : 938 - 963
  • [36] Liver transplantation and non-alcoholic fatty liver disease
    Petros Zezos
    Eberhard L Renner
    World Journal of Gastroenterology, 2014, (42) : 15532 - 15538
  • [37] Sex difference in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Tomiya, Tomoaki
    HEPATOLOGY RESEARCH, 2010, 40 (01) : 108 - 110
  • [38] Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
    Wu, Dongqing
    Zhu, Huaqing
    Wang, Hua
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [39] PTEN in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis and Cancer
    Peyrou, Marion
    Bourgoin, Lucie
    Foti, Michelangelo
    DIGESTIVE DISEASES, 2010, 28 (01) : 236 - 246
  • [40] Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis - NASH
    Keller, KM
    MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (08) : 864 - 869